Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06352892
Status:
COMPLETED
Last Update Posted:
2024-05-29
First Post:
2024-04-03
Brief Title:
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 1 Open-label Randomized Parallel-group Single-dose Study to Evaluate the Pharmacokinetics Safety and Tolerability of AMG 133 Administered Subcutaneously in Chinese Subjects With Obesity or Overweight
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of the study is to assess the pharmacokinetics PK of Maridebart Cafraglutide after a single subcutaneous SC administration in overweight or obese Chinese participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None